Xu Yu, Wang Ning, Tan Hor-Yue, Li Sha, Zhang Cheng, Feng Yibin
School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
Front Microbiol. 2020 Feb 21;11:219. doi: 10.3389/fmicb.2020.00219. eCollection 2020.
Obesity and its metabolic syndrome, including liver disorders and type 2 diabetes, are a worldwide epidemic and are intimately linked to diet. The gut microbiota interaction has been pointed to as a hot topic of research in the treatment of obesity and related metabolic diseases by influencing energy metabolism and the immune system. In terms of the novel beneficial microbes identified, () colonizes the mucosa layer of the gut and modulates basal metabolism. is consistently correlated with obesity. The causal beneficial impact of treatment on obesity is coming to light, having been proved by a variety of animal models and human studies. has been characterized as a beneficial player in body metabolism and has great prospects for treatments of the metabolic disorders associated with obesity, as well as being considered for next-generation therapeutic agents. This paper aimed to investigate the basic mechanism underlying the relation of to obesity and its host interactions, as identified in recent discoveries, facilitating the establishment of the causal relationship in -associated therapeutic supplement in humans.
肥胖及其代谢综合征，包括肝脏疾病和2型糖尿病，是一种全球性的流行病，并且与饮食密切相关。肠道微生物群的相互作用已被指出是肥胖及相关代谢疾病治疗研究中的一个热门话题，因为它会影响能量代谢和免疫系统。就已鉴定出的新型有益微生物而言，（）定殖于肠道黏膜层并调节基础代谢。（）与肥胖始终相关。（）治疗对肥胖的因果有益影响正在显现，这已被各种动物模型和人体研究证实。（）已被确定为身体代谢中的有益因素，在治疗与肥胖相关的代谢紊乱方面具有广阔前景，并且被视为下一代治疗药物。本文旨在研究（）与肥胖及其宿主相互作用关系的基本机制，正如最近的发现所确定的那样，以促进人类中与（）相关的治疗性补充剂因果关系的确立。
